report
analyt
interfer
antiescherichia
coli
protein
ep
antibodi
human
sera
residu
ep
recombin
nucleocapsid
proteinbas
enzymelink
immunosorb
assay
possibl
sourc
fals
posit
sever
acut
respiratori
syndrom
serodiagnosi
rate
fals
posit
significantli
reduc
ad
mous
antiep
antiserum
block
step
sever
acut
respiratori
syndrom
sar
emerg
infecti
diseas
caus
zoonot
coronaviru
cov
name
sarscov
viral
nucleocapsid
n
protein
compos
amino
acid
estim
molecular
mass
kda
current
sever
recombin
n
protein
rnp
base
serodiagnost
system
use
either
antigencaptur
indirect
enzymelink
immunosorb
assay
elisa
system
develop
howev
small
portion
fals
posit
report
make
diagnost
tool
less
favor
earli
detect
possibl
resurfac
sar
infect
presenc
antiep
antibodi
ab
sera
healthi
human
wide
report
herein
hypothes
interact
residu
escherichia
coli
protein
rep
present
coat
antigen
natur
occur
anti
coli
protein
antiep
antibodi
healthi
human
may
serv
potenti
interfer
studi
overlap
fragment
encod
complet
open
read
frame
n
gene
strain
design
rnp
rnp
express
use
prset
protein
express
system
invitrogen
purifi
use
nickelcharg
sepharos
fastflow
matrix
amersham
bioscienc
accord
manufactur
instruct
found
studi
rnp
amino
acid
show
highest
antigen
compar
fulllength
rnp
data
shown
chosen
rnp
antigen
subsequ
immunoassay
due
rel
high
express
level
gml
purifi
rnp
analyz
use
silverstainingbas
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
western
blot
serum
convalesc
sar
patient
show
singl
promin
band
observ
kda
fig
puriti
rnp
determin
light
densitometri
biorad
rnp
base
elisa
first
assess
screen
serum
sampl
healthi
individu
convalesc
sar
patient
briefli
well
immobil
ng
rnp
wash
standard
block
procedur
block
buffer
milk
powder
phosphatebuff
salin
tween
human
serum
sampl
volvol
appli
incub
perform
min
follow
incub
horseradish
peroxidas
hrp
mous
antihuman
immunoglobulin
g
igg
volvol
zyme
min
absorb
measur
nm
addit
tmb
solut
zyme
sulfur
acid
rel
level
sar
antibodi
determin
calcul
rel
absorb
r
accord
equat
sampl
absorb
blank
absorb
posit
control
absorb
blank
absorb
cutoff
valu
assay
r
control
serum
sampl
time
standard
deviat
eight
serum
sampl
sar
patient
posit
rnp
elisa
commerci
elisa
kit
beij
huada
gbi
biotechnolog
viral
lysat
use
antigen
howev
serum
sampl
regard
fals
posit
sampl
show
posit
rnp
elisa
neg
commerci
elisa
kit
demonstr
potenti
exist
rep
system
mous
antiep
antiserum
rais
intramuscular
immun
balbc
mice
crude
prepar
ep
presenc
rep
purifi
rnp
illustr
western
blot
mous
antiep
antiserum
volvol
follow
goat
antimous
igg
heavi
plu
light
chain
hrp
conjug
volvol
zyme
fig
demonstr
presenc
antiep
ab
falseposit
serum
sampl
western
blot
perform
two
fals
posit
show
highest
r
valu
design
crude
ep
rnp
collect
differ
stage
purif
detect
hrpmous
antihuman
igg
volvol
zyme
fig
e
although
intens
correspond
band
rep
purifi
rnp
rel
weak
fig
band
may
accumul
contribut
overal
optic
densiti
read
rnp
elisa
lead
falseposit
signal
tri
reduc
analyt
interfer
human
antiep
ab
rep
rnp
mous
antiep
antiserum
use
addit
block
reagent
immunoblock
capac
mous
antiep
antiserum
demonstr
ad
differ
dilut
mous
antiep
antiserum
block
step
western
blot
procedur
serum
sampl
crude
ep
fig
modifi
block
step
appli
rnp
elisa
dilut
mous
antiep
antiserum
found
maximum
block
effici
data
shown
influenc
modif
sensit
system
found
minim
indic
r
valu
eight
sarsposit
sera
remain
unaffect
without
immunoblock
tabl
last
column
therefor
dilut
mous
antiep
antiserum
ad
block
buffer
modifi
block
procedur
r
valu
fals
posit
standard
rnp
elisa
decreas
significantli
p
pair
student
test
modifi
block
step
signific
decreas
observ
normal
mice
serum
use
instead
tabl
modifi
block
step
block
effici
falseposit
sera
sampl
show
r
valu
higher
cutoff
tabl
indic
signific
improv
specif
rnp
differ
two
block
step
defin
pair
student
test
signific
level
r
valu
fals
posit
standard
rnp
elisa
decreas
significantli
modifi
immunoblock
procedur
block
effici
rstandard
rmodifi
rstandard
rstandard
rmodifi
repres
r
valu
standard
modifi
block
respect
n
repres
total
number
sampl
fals
posit
obvious
higher
two
serum
data
group
b
p
c
antiep
mous
antiep
antiserum
nm
normal
mous
serum
e
na
applic
parallel
wide
document
presenc
antiep
ab
healthi
human
sera
interact
rep
e
coliexpress
antigenbas
elisa
system
contribut
fals
posit
also
report
despit
fact
rnpbase
elisa
system
wide
use
tool
detect
sarscov
infect
high
rate
fals
posit
may
lead
mislead
conclus
diagnosi
seropreval
studi
sar
conclus
suggest
immunoblock
mous
antiep
antiserum
altern
way
reduc
number
fals
posit
caus
analyt
interfer
rep
e
coliexpress
antigen
antiep
ab
human
sera
conflict
interest
declar
